Pharmaceutical Research

, Volume 28, Issue 7, pp 1520–1530 | Cite as

Agarose Surface Coating Influences Intracellular Accumulation and Enhances Payload Stability of a Nano-delivery System

  • Enrica De Rosa
  • Ciro Chiappini
  • Dongmei Fan
  • Xuewu Liu
  • Mauro Ferrari
  • Ennio Tasciotti
Research Paper

ABSTRACT

Purpose

Protein therapeutics often require repeated administrations of drug over a long period of time. Protein instability is a major obstacle to the development of systems for their controlled and sustained release. We describe a surface modification of nanoporous silicon particles (NSP) with an agarose hydrogel matrix that enhances their ability to load and release proteins, influencing intracellular delivery and preserving molecular stability.

Methods

We developed and characterized an agarose surface modification of NSP. Stability of the released protein after enzymatic treatment of loaded particles was evaluated with SDS-page and HPLC analysis. FITC-conjugated BSA was chosen as probe protein and intracellular delivery evaluated by fluorescence microscopy.

Results

We showed that agarose coating does not affect NSP protein release rate, while fewer digestion products were found in the released solution after all the enzymatic treatments. Confocal images show that the hydrogel coating improves intracellular delivery, specifically within the nucleus, without affecting the internalization process.

Conclusions

This modification of porous silicon adds to its tunability, biocompatibility, and biodegradability the ability to preserve protein integrity during delivery without affecting release rates and internalization dynamics. Moreover, it may allow the silicon particles to function as protein carriers that enable control of cell function.

KEY WORDS

agarose hydrogel intracellular delivery nanopores porous silicon protein 

ABBREVIATIONS

A1

agarose composition 0.125%

A2

agarose composition 0.05%

Ag

agarose coated

APTES

aminopropyltriethoxysilane

BSA

bovine serum albumin

FACS

fluorescence activated cell sorting

FGF

fibroblast growth factor

HPLC

high performance liquid chromatography

HUVEC

human umbilical vein endothelial cells

NC

bare / not coated

NSPs

nanoporous silicon particles

PLGA

poly(lactic-co-glycolic acid)

pSi

porous silicon

SDS-page

sodium dodecyl sulfate polyacrylamide gel electrophoresis

SEM

scanning electron microscope

SiN

silicon nitride

VEGF

vascular endothelial growth factor

Supplementary material

11095_2011_453_MOESM1_ESM.docx (5.5 mb)
ESM 1(DOCX 5663 kb)

REFERENCES

  1. 1.
    Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7:21–39.PubMedCrossRefGoogle Scholar
  2. 2.
    Murphyand WJ, Longo DL. Growth hormone as an immunomodulating therapeutic agent. Immunol Today. 2000;21:211–3.CrossRefGoogle Scholar
  3. 3.
    Chen DJ, Osterrieder N, Metzger SM, Buckles E, Doody AM, DeLisa MP, et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc Natl Acad Sci. 107:3099–3104.Google Scholar
  4. 4.
    Rosado JL, Solomons NW, Lisker R, Bourges H. Enzyme replacement therapy for primary adult lactase deficiency. Effective reduction of lactose malabsorption and milk intolerance by direct addition of [beta]-galactosidase to milk at mealtime. Gastroenterology. 1984;87:1072–82.PubMedGoogle Scholar
  5. 5.
    Haase M. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2002;100:4242.PubMedCrossRefGoogle Scholar
  6. 6.
    Mease PJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor [alpha]. N Engl J Med. 2002;346:1349–56.PubMedCrossRefGoogle Scholar
  8. 8.
    Szmuness W. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303:833–41.PubMedCrossRefGoogle Scholar
  9. 9.
    Shi L. Gardasil: prophylactic human papillomavirus vaccine development [mdash] from bench top to bed-side. Clin Pharm Ther. 2007;81:259–64.CrossRefGoogle Scholar
  10. 10.
    Sodee DB. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. Urology. 2000;56:988–93.PubMedCrossRefGoogle Scholar
  11. 11.
    Taillefer R, Edell S, Innes G, Lister-James J. Acute thromboscintigraphy with Tc-99 m-apcitide: results of the phase 3 multicenter clinical trial comparing Tc-99 m-apcitide scintigraphy with contrast venography for imaging acute DVT. J Nucl Med. 2000;41:1214–23.PubMedGoogle Scholar
  12. 12.
    Meier CA. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab. 1994;78:188–96.PubMedCrossRefGoogle Scholar
  13. 13.
    VeÌgvaÌriand A, Marko-Varga G. Clinical Protein Science and Bioanalytical Mass Spectrometry with an Emphasis on Lung Cancer. Chem Rev. 2010;110:3278–98.CrossRefGoogle Scholar
  14. 14.
    McVey D, Hamilton MM, Hsu C, King CR, Brough DE, Wei LL. Repeat Administration of Proteins to the Eye With a Single Intraocular Injection of an Adenovirus Vector. Mol Ther. 2008;16:1444–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Mahmoodand I, Green MD. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet. 2005;44:331–47.CrossRefGoogle Scholar
  16. 16.
    Putneyand SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Nat Biotech. 1998;16:153–7.CrossRefGoogle Scholar
  17. 17.
    Fu K, Klibanov AM, Langer R. Protein stability in controlled-release systems. Nat Biotech. 2000;18:24–5.CrossRefGoogle Scholar
  18. 18.
    Tayaliaand P, Mooney DJ. Controlled growth factor delivery for tissue engineering. Adv Mater. 2009;21:3269–85.CrossRefGoogle Scholar
  19. 19.
    Edelman ER, Nugent MA, Karnovsky MJ. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc Natl Acad Sci USA. 1993;90:1513–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation. 1996;94:1074–82.PubMedGoogle Scholar
  21. 21.
    Wang J, Chua KM, Wang C-H. Stabilization and encapsulation of human immunoglobulin G into biodegradable microspheres. J Colloid Interface Sci. 2004;271:92–101.PubMedCrossRefGoogle Scholar
  22. 22.
    van de Weert M, Hennink WE, Jiskoot W. Protein Instability in Poly(Lactic-co-Glycolic Acid) microparticles. Pharm Res. 2000;17:1159–67.PubMedCrossRefGoogle Scholar
  23. 23.
    Sah H. Protein instability toward organic solvent/water emulsification: implications for protein microencapsulation into microspheres. PDA J Pharm Sci Technol. 1999;53:3–10.PubMedGoogle Scholar
  24. 24.
    Cleland JL, Mac A, Boyd B, Yang J, Duenas ET, Yeung D, et al. The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res. 1997;14:420–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Canham LT. Bioactive silicon structure fabrication through nanoetching techniques. Advanced Materials. 1995; 7.Google Scholar
  26. 26.
    Voelcker NH, Khung Y-L, Low SP, Clements LR, Williams KA. Porous Silicon Science and Technology Conference, Valencia, 2010.Google Scholar
  27. 27.
    Herino R. In: Canham LT, editor. The properties of porous silicon. London: INSPEC-IEE; 1997.Google Scholar
  28. 28.
    Salonen J, Kaukonen AM, Hirvonen J, Lehto VP. Mesoporous silicon in drug delivery applications. J Pharm Sci. 2008;97:632–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Chiappini C, Tasciotti E, Fakhoury JR, Fine D, Pullan L, Wang Y-C, et al. Tailored porous silicon microparticles: fabrication and properties. Chemphyschem. 2010;11:1029–35.PubMedGoogle Scholar
  30. 30.
    Cunin F, Schmedake TA, Link JR, Li YY, Koh J, Bhatia SN, et al. Biomolecular screening with encoded porous-silicon photonic crystals. Nat Mater. 2002;1:39–41.PubMedCrossRefGoogle Scholar
  31. 31.
    Linsmeier J, Wüst K, Schenk H, Hilpert U, Ossau W, Fricke J, et al. Chemical surface modification of porous silicon using tetraethoxysilane. Thin Solid Films. 1997;297:26–30.CrossRefGoogle Scholar
  32. 32.
    Gurtner C, Wun AW, Sailor MJ. Surface modification of porous silicon by electrochemical reduction of organo halides. Angew Chem Int Ed. 1999;38:1966–8.CrossRefGoogle Scholar
  33. 33.
    Salonen J, Laitinen L, Kaukonen AM, Tuura J, Björkqvist M, Heikkilä T, et al. Mesoporous silicon microparticles for oral drug delivery: Loading and release of five model drugs. J Control Release. 2005;108:362–74.PubMedCrossRefGoogle Scholar
  34. 34.
    Prestidge CA, Barnes TJ, Lau CH, Barnett C, Loni A, Canham L. Mesoporous silicon: a platform for the delivery of therapeutics. Expert Opin Drug Deliv. 2007;4:101–10.PubMedCrossRefGoogle Scholar
  35. 35.
    Tasciotti E, Liu XW, Bhavane R, Plant K, Leonard AD, Price BK, et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol. 2008;3:151–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Prestidge CA, Barnes TJ, Mierczynska-Vasilev A, Kempson I, Peddie F, Barnett C. Peptide and protein loading into porous silicon wafers. Phys Status Solidi A. 2008;205:311–5.CrossRefGoogle Scholar
  37. 37.
    Prestidge CA, Barnes TJ, Mierczynska-Vasilev A, Skinner W, Peddie F, Barnett C. Loading and release of a model protein from porous silicon powders. Phys Status Solidi A. 2007;204:3361–6.CrossRefGoogle Scholar
  38. 38.
    Serda RE, Godin B, Blanco E, Chiappini C, Ferrari M. Multi-stage delivery nano-particle systems for therapeutic applications. Biochimica et Biophysica Acta (BBA)—General Subjects. In Press, Corrected Proof:in press (2010).Google Scholar
  39. 39.
    Kilpeläinen M, Riikonen J, Vlasova MA, Huotari A, Lehto VP, Salonen J, et al. In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles. J Control Release. 2009;137:166–70.PubMedCrossRefGoogle Scholar
  40. 40.
    Anglin EJ, Schwartz MP, Ng VP, Perelman LA, Sailor MJ. Engineering the chemistry and nanostructure of porous silicon fabry-pérot films for loading and release of a steroid. Langmuir. 2004;20:11264–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010;70:3687–96.PubMedCrossRefGoogle Scholar
  42. 42.
    Tanaka T, Godin B, Bhavane R, Nieves-Alicea R, Gu J, Liu X, et al. In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. Int J Pharm. 2010;402:190–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Decuzzi P, Godin B, Tanaka T, Lee SY, Chiappini C, Liu X, et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release. 2010;141:320–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Ferrari M. Nanogeometry Beyond drug delivery Nat Nano. 2008;3:131–2.Google Scholar
  45. 45.
    Godin B, Gu J, Serda RE, Bhavane R, Tasciotti E, Chiappini C, et al. Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A. 2010;94A:1236–43.Google Scholar
  46. 46.
    Serda RE, Mack A, Pulikkathara M, Zaske AM, Chiappini C, Fakhoury JR, et al. Cellular association and assembly of a multistage delivery system. Small. 2010;6:1329–40.PubMedCrossRefGoogle Scholar
  47. 47.
    Ferrati S, Mack A, Chiappini C, Liu X, Bean AJ, Ferrari M, et al. Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale. 2010;2:1512–20.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Enrica De Rosa
    • 1
  • Ciro Chiappini
    • 2
  • Dongmei Fan
    • 1
  • Xuewu Liu
    • 1
  • Mauro Ferrari
    • 1
  • Ennio Tasciotti
    • 1
  1. 1.The Methodist Hospital Research Institute (TMHRI)HoustonUSA
  2. 2.University of Texas at AustinAustinUSA

Personalised recommendations